Stock Analysis

XBiotech Full Year 2022 Earnings: US$1.08 loss per share (vs US$0.58 loss in FY 2021)

Source: Shutterstock

XBiotech (NASDAQ:XBIT) Full Year 2022 Results

Key Financial Results

  • Net loss: US$32.9m (loss widened by 89% from FY 2021).
  • US$1.08 loss per share (further deteriorated from US$0.58 loss in FY 2021).
NasdaqGS:XBIT Earnings and Revenue History March 17th 2023

All figures shown in the chart above are for the trailing 12 month (TTM) period

XBiotech shares are up 2.4% from a week ago.

Risk Analysis

We don't want to rain on the parade too much, but we did also find 2 warning signs for XBiotech (1 is a bit concerning!) that you need to be mindful of.

Valuation is complex, but we're helping make it simple.

Find out whether XBiotech is potentially over or undervalued by checking out our comprehensive analysis, which includes fair value estimates, risks and warnings, dividends, insider transactions and financial health.

View the Free Analysis